Time to Consider HPV Vaccination after Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1033-1036

  Tedeschi, Sara K ^a   Savani, Bipin N ^a   Jagasia, Madan ^a   Engelhardt, Brian ^a   Anasetti, Claudio ^b   Barrett, A John ^c   Lee, Stephanie ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d USA   (United States)

Author keywords

HPV; Secondary cancer; Squamous cell carcinoma; Transplantation; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CONDYLOMA ACUMINATUM; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METASTASIS; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77954313785     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.007     Document Type: Editorial

References (24)

1. Savani B.N., Goodman S., Barrett A.J. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?. Clin Cancer Res 2009, 15:2219-2221.
2. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
3. Dubina M., Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 2009, 31:561-573.
4. Savani B.N., Stratton P., Shenoy A., et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008, 14:1072-1075.
5. Villeneuve P.J., Schaubel D.E., Fenton S.S., et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007, 7:941-948.
6. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 24(Suppl 1):S16-S22.
7. De Vuyst H., Franceschi S. Human papillomavirus vaccines in HIV-positive men and women. Curr Opin Oncol 2007, 19:470-475.
8. Strickler H.D., Palefsky J.M., Shah K.V., et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003, 95:1062-1071.
9. Moscicki A.B. Human papillomavirus infection in adolescents. Pediatr Clin North Am 1999, 46:783-807.
10. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046.
11. Chaturvedi A.K., Madeleine M.M., Biggar R.J., Engels E.A. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120-1130.
12. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
13. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
14. Tarkowski T.A., Koumans E.H., Sawyer M., et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004, 189:46-50.
15. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
16. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
17. Rose B., Wilkins D., Li W., et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. Transplantation 2006, 82:570-573.
18. Barr E., Sings H.L. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008, 26:6244-6257.
19. Kenter G.G., Welters M.J., Valentijn A.R., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
20. Block S.L., Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118:2135-2145.
21. Giuliano A, Palefsky J. Efficacy against male genital disease and infection IPC 2009. 25th International Papillomavirus Conference & Clinical Workshop, May 8-14, 2009, Malmo, Sweden; pp. 01-07, 2009.
22. Guris D. The immunogenicity of Quadrivalent HPV (types 6/11/16/18) vaccine in young men. 25th International Papillomavirus Conference & Clinical Workshop, May 8-14, 2009, Malmo, Sweden; p. 577, 2009.
23. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:201-209.
24. Weinberg A, Song LY, Handelsman E. Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus infection in HIV-infected children: IMPAACT P1047. 15th Conference on Retroviruses and Opportunisitic Infections, Feb 3-6, Boston, MA; p. 619a, 2008.